EP2675471A4 - HSA-RELATED COMPOSITIONS AND USE PROCESSES - Google Patents

HSA-RELATED COMPOSITIONS AND USE PROCESSES

Info

Publication number
EP2675471A4
EP2675471A4 EP11858565.2A EP11858565A EP2675471A4 EP 2675471 A4 EP2675471 A4 EP 2675471A4 EP 11858565 A EP11858565 A EP 11858565A EP 2675471 A4 EP2675471 A4 EP 2675471A4
Authority
EP
European Patent Office
Prior art keywords
hsa
methods
related compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11858565.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2675471A1 (en
Inventor
Changshou Gao
Chaity Chaudhury
Xiaotao Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/024855 external-priority patent/WO2011103076A1/en
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of EP2675471A1 publication Critical patent/EP2675471A1/en
Publication of EP2675471A4 publication Critical patent/EP2675471A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP11858565.2A 2011-02-15 2011-08-09 HSA-RELATED COMPOSITIONS AND USE PROCESSES Withdrawn EP2675471A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2011/024855 WO2011103076A1 (en) 2010-02-16 2011-02-15 Hsa-related compositions and methods of use
PCT/US2011/047040 WO2012112188A1 (en) 2011-02-15 2011-08-09 Hsa-related compositions and methods of use

Publications (2)

Publication Number Publication Date
EP2675471A1 EP2675471A1 (en) 2013-12-25
EP2675471A4 true EP2675471A4 (en) 2015-01-28

Family

ID=46675795

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11858565.2A Withdrawn EP2675471A4 (en) 2011-02-15 2011-08-09 HSA-RELATED COMPOSITIONS AND USE PROCESSES

Country Status (7)

Country Link
EP (1) EP2675471A4 (enExample)
JP (1) JP2014510518A (enExample)
KR (1) KR20140012094A (enExample)
CN (1) CN103379915A (enExample)
AU (1) AU2011359378A1 (enExample)
CA (1) CA2826683A1 (enExample)
WO (1) WO2012112188A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
BR112012009450A2 (pt) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
CA2789337A1 (en) * 2010-02-16 2011-08-25 Medimmune, Llc Hsa-related compositions and methods of use
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
BR112013031943B1 (pt) 2011-06-13 2021-10-13 Csl Limited Composição que compreende proteínas e anticorpos contra g-csfr
EP2780364A2 (en) * 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
ES2664328T3 (es) 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
KR20150118123A (ko) 2013-02-16 2015-10-21 노보자임스 바이오파마 디케이 에이/에스 약동학적 동물 모델
KR102191654B1 (ko) * 2013-03-15 2020-12-16 애피바디 에이비 신규 폴리펩티드
WO2014198834A1 (en) * 2013-06-12 2014-12-18 Pharis Biotec Gmbh Peptides with antagonistic activities against natural cxcr4
US20160222087A1 (en) * 2013-09-13 2016-08-04 Novozymes Biopharma Dk A/S Albumin variants
JP6306700B2 (ja) * 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
CN107428817B (zh) 2015-03-12 2022-07-12 免疫医疗有限责任公司 纯化白蛋白融合蛋白的方法
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
WO2017053617A1 (en) * 2015-09-23 2017-03-30 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
JP7146637B2 (ja) 2015-12-22 2022-10-04 アルブミディクス リミティド 改善されたタンパク質発現株
CN108431204A (zh) 2015-12-22 2018-08-21 阿尔布梅迪克斯医疗有限公司 改良的表达蛋白质的菌株
US20210333279A1 (en) 2016-11-04 2021-10-28 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
CA3064037A1 (en) 2017-06-20 2018-12-27 Albumedix Ltd Improved protein expression strains
ES2939461T3 (es) 2017-11-29 2023-04-24 Csl Ltd Método para tratar o prevenir la lesión por isquemia-reperfusión
WO2019178645A1 (en) 2018-03-23 2019-09-26 Csl Limited Method of treating asthma
SG11202010596PA (en) 2018-05-16 2020-11-27 Csl Ltd Soluble complement receptor type 1 variants and uses thereof
KR20210111242A (ko) 2018-10-29 2021-09-10 바이오젠 엠에이 인코포레이티드 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체
US20230220048A1 (en) 2019-09-06 2023-07-13 Novartis Ag Therapeutic fusion proteins
US20230000774A1 (en) 2019-12-04 2023-01-05 Albumedix Limited Methods and compositions produced thereby
WO2022166720A1 (zh) * 2021-02-05 2022-08-11 华南理工大学 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用
CN113912730B (zh) * 2021-12-14 2022-03-04 北京科诺信诚科技有限公司 缓释的抗FcRn抗体或抗原结合片段及其应用
EP4608448A1 (en) 2022-10-28 2025-09-03 Aarhus Universitet Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response
EP4442251A1 (en) 2023-04-05 2024-10-09 Albumedix Ltd Formulations and uses thereof
WO2025007195A1 (en) 2023-07-05 2025-01-09 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease
WO2025158071A1 (en) 2024-01-26 2025-07-31 Sartorius Albumedix Limited Retroviral preparations containing albumin for enhancing transduction efficiency, uses thereof for cell transduction
EP4703468A1 (en) 2024-08-29 2026-03-04 Sartorius Albumedix Limited Methods and uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103076A1 (en) * 2010-02-16 2011-08-25 Medlmmune, Llc Hsa-related compositions and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404270D0 (en) * 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
EA022201B1 (ru) * 2008-04-11 2015-11-30 Мерримак Фармасьютикалз, Инк. Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
CN102458442B (zh) * 2009-04-08 2016-06-29 加利福尼亚大学董事会 具有受控血清药代动力学的人蛋白支架

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103076A1 (en) * 2010-02-16 2011-08-25 Medlmmune, Llc Hsa-related compositions and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012112188A1 *

Also Published As

Publication number Publication date
CA2826683A1 (en) 2012-08-23
EP2675471A1 (en) 2013-12-25
AU2011359378A1 (en) 2013-10-03
CN103379915A (zh) 2013-10-30
JP2014510518A (ja) 2014-05-01
KR20140012094A (ko) 2014-01-29
WO2012112188A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
PH12013501427A1 (en) Melanin modification compositions and methods of use
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
IL232977B (en) Intra-episode dexmedetomidine preparations and methods of using them
AP3965A (en) Anthelminitic compounds and compositions and method of using thereof
GB201411462D0 (en) Prebiotic formulations and methods of use
SG11201501499SA (en) Multi-functional compositions and methods of use
EP2834322A4 (en) BIOCHARBON COMPOSITIONS AND METHODS OF USE
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
PL3366143T3 (pl) Kompozycje probiotyczne i sposoby
SG11201400668SA (en) Wnt compositions and therapeutic uses of such compositions
SG11201400567QA (en) Cd40l-specific tn3-derived scaffolds and methods of use thereof
SG11201501381PA (en) Topical compositions and methods of use
IL239631A0 (en) Anti-integrin cell 1 antibody preparations and methods of using them
IL235968A0 (en) Polysaccharide preparations and methods of use
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2668044A4 (en) COMPOSITIONS AND THEIR USE
ZA201308892B (en) Compositions and methods
IL239623A0 (en) Methods and preparations for administering oxybutynin
PL2736328T3 (pl) Biocydowe kompozycje oraz sposoby stosowania
PL2736339T3 (pl) Biocydowe kompozycje oraz sposoby stosowania
GB201116340D0 (en) Compositions and methods
AU2012901658A0 (en) Compositions and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192466

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20150108

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/765 20060101ALI20141222BHEP

Ipc: A61K 47/48 20060101ALI20141222BHEP

Ipc: A61K 38/38 20060101AFI20141222BHEP

17Q First examination report despatched

Effective date: 20150907

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160318

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1192466

Country of ref document: HK